Corbus Pharmaceuticals Hldgs Inc (CRBP)

$8.42 -0.10 (-1.17%)
Market Cap 98.63M
Revenue (ttm) 0.00
Net Income (ttm) -40.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 108,016
Avg Vol 161,138
Day's Range N/A - N/A
Shares Out 12.24M
Stochastic %K 86%
Beta 3.05
Analysts Strong Sell
Price Target $42.89

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 963 0100
Fax: 617 663 6085
Address:
500 River Ridge Drive, Norwood, United States
MakeThingsFly
MakeThingsFly Jul. 17 at 12:15 AM
$CRBP https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0002052113-25-002503/primary_doc.html
0 · Reply
MakeThingsFly
MakeThingsFly Jul. 17 at 12:07 AM
$CRBP BlackRock just picked up about 350,000 shares (2.9%). Looking forward to the end of Q3 and 2026!!
0 · Reply
justme_DC
justme_DC Jul. 16 at 7:41 PM
$CRBP Would so love a positive / substantive PR right about NOW
0 · Reply
eaglesflyhi
eaglesflyhi Jul. 16 at 5:40 PM
$JDZG do a $CRBP who post split eventually ran to $60+
0 · Reply
BuyHighSellLow4Life
BuyHighSellLow4Life Jul. 15 at 1:20 PM
$CRBP liking this action, keep it up you POS
0 · Reply
BuyHighSellLow4Life
BuyHighSellLow4Life Jul. 9 at 2:58 PM
$CRBP green dildo let’s go
0 · Reply
justme_DC
justme_DC Jul. 2 at 8:01 PM
$CRBP This is the one exception where I take strong notice of SI. With ~11 days to cover, wow wouldn't it be nice for some unexpected positive catalyst to be announced. Great day though regardless....I will take it!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 30 at 12:08 PM
$CRBP Corbus Pharmaceuticals initiates MAD portion of its Phase 1 trial for CRB-913 Corbus Pharmaceuticals announced the initiation of the multiple ascending dose, MAD, portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety and pharmacokinetics data analysis of the single ascending dose, SAD, study launched in March. The MAD portion of this clinical study is scheduled for completion in the third quarter of this year. The MAD portion of the Phase 1 trial is designed to test a once-daily dosing of CRB-913 for 7 days. Similarly to the SAD study, the MAD study is undertaken with healthy volunteers and focuses on safety, tolerability and PK of increasing doses of CRB-913. The study is being conducted in the United States.
0 · Reply
shlomiko
shlomiko Jun. 26 at 3:53 PM
$CRBP
0 · Reply
MGBuckeye
MGBuckeye Jun. 26 at 3:51 PM
$CRBP down nearly 10%. Why?
0 · Reply
Latest News on CRBP
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 25, 2025, 8:00 AM EDT - 22 days ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 24, 2025, 4:05 PM EDT - 22 days ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Jun 17, 2025, 3:42 PM EDT - 4 weeks ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Mar 28, 2025, 8:00 AM EDT - 3 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 14, 2025, 7:30 AM EST - 5 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Feb 11, 2025, 7:30 AM EST - 5 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 8:00 AM EST - 6 months ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 6 months ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Dec 9, 2024, 7:00 AM EST - 7 months ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Dec 3, 2024, 7:00 AM EST - 8 months ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Nov 11, 2024, 4:12 AM EST - 8 months ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Oct 16, 2024, 8:00 AM EDT - 9 months ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 26, 2024, 8:00 AM EDT - 10 months ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Sep 23, 2024, 2:01 PM EDT - 10 months ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 11 months ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 20, 2024, 8:00 AM EDT - 11 months ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Mar 6, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 28, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 9:50 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 2, 2024, 4:01 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Corbus Pharmaceuticals Announces Pricing of Public Offering

Jan 31, 2024, 9:19 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Proposed Public Offering

Jan 30, 2024, 6:55 PM EST - 1 year ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 30, 2024, 7:13 AM EST - 1 year ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 2:17 PM EST - 1 year ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 29, 2024, 7:18 AM EST - 1 year ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Jan 26, 2024, 7:30 AM EST - 1 year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Jan 23, 2024, 8:00 AM EST - 1 year ago

Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Jan 9, 2024, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Dec 18, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert' Series (Session 2) on CRB-701 on October 10, 2023

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

MakeThingsFly
MakeThingsFly Jul. 17 at 12:15 AM
$CRBP https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0002052113-25-002503/primary_doc.html
0 · Reply
MakeThingsFly
MakeThingsFly Jul. 17 at 12:07 AM
$CRBP BlackRock just picked up about 350,000 shares (2.9%). Looking forward to the end of Q3 and 2026!!
0 · Reply
justme_DC
justme_DC Jul. 16 at 7:41 PM
$CRBP Would so love a positive / substantive PR right about NOW
0 · Reply
eaglesflyhi
eaglesflyhi Jul. 16 at 5:40 PM
$JDZG do a $CRBP who post split eventually ran to $60+
0 · Reply
BuyHighSellLow4Life
BuyHighSellLow4Life Jul. 15 at 1:20 PM
$CRBP liking this action, keep it up you POS
0 · Reply
BuyHighSellLow4Life
BuyHighSellLow4Life Jul. 9 at 2:58 PM
$CRBP green dildo let’s go
0 · Reply
justme_DC
justme_DC Jul. 2 at 8:01 PM
$CRBP This is the one exception where I take strong notice of SI. With ~11 days to cover, wow wouldn't it be nice for some unexpected positive catalyst to be announced. Great day though regardless....I will take it!
0 · Reply
DonCorleone77
DonCorleone77 Jun. 30 at 12:08 PM
$CRBP Corbus Pharmaceuticals initiates MAD portion of its Phase 1 trial for CRB-913 Corbus Pharmaceuticals announced the initiation of the multiple ascending dose, MAD, portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety and pharmacokinetics data analysis of the single ascending dose, SAD, study launched in March. The MAD portion of this clinical study is scheduled for completion in the third quarter of this year. The MAD portion of the Phase 1 trial is designed to test a once-daily dosing of CRB-913 for 7 days. Similarly to the SAD study, the MAD study is undertaken with healthy volunteers and focuses on safety, tolerability and PK of increasing doses of CRB-913. The study is being conducted in the United States.
0 · Reply
shlomiko
shlomiko Jun. 26 at 3:53 PM
$CRBP
0 · Reply
MGBuckeye
MGBuckeye Jun. 26 at 3:51 PM
$CRBP down nearly 10%. Why?
0 · Reply
RlCK
RlCK Jun. 25 at 10:32 PM
$CRBP average at 78. Almost there! 😂😂😂
1 · Reply
Cricket23
Cricket23 Jun. 25 at 6:50 PM
$CRBP Very strong move to the upside from CRBP today on high volume! This has lots of room to run much higher! Their pipeline of products they offer is very valuable.
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 19 at 5:59 AM
$CRBP Corbus’ experimental drug CRB-701 targets a hot oncology pathway. With a long cash runway, CRBP might be massively undervalued. https://biotechhealthx.com/biotech-news/corbus-crbp-has-149m-in-cash-a-cancer-drug-that-could-shock-wall-street/
0 · Reply
sageinvestor
sageinvestor Jun. 18 at 3:19 PM
$CRBP https://www.ainvest.com/news/slimming-odds-corbus-crb-913-outpace-novo-monlunabant-obesity-market-2506/
0 · Reply
birdmine
birdmine Jun. 13 at 12:06 PM
$CRBP 9.50 in the premarket. Can it hit 10?
0 · Reply
MoneyMcDuck
MoneyMcDuck Jun. 11 at 6:23 PM
$CRBP is setting up cleanly—price recently reclaimed key moving averages and continues to grind higher off April lows. Trend strength is intact, even without a major volume spike. Their lead program targets cancer and metabolic disease with a novel mTORC1 inhibitor. With $130M+ in cash and no debt, they’re funded deep into 2027. ✅ Low float ✅ Bullish structure ✅ $6B+ target market Watch dips near $8.60 or strength above $9.30. Solid setup with room to run. 🔥
1 · Reply
Bornjever
Bornjever Jun. 11 at 1:50 PM
$CRBP similar in less dramatic way is ARQT with focus on skin disease but really helping people with 4th approval came on 0522 and stock price actually dropped with shorts being ones to see small bio without flashy cancer meds with 350 million or more in 2025 revenue and 450 million in 2026 but each time more revenue price goes down and you just have to know what you hold and eventually you will be rewarded VERY
0 · Reply
shoagh12
shoagh12 Jun. 9 at 11:24 AM
$CRBP Double up today
0 · Reply
StockStratigizer
StockStratigizer Jun. 6 at 6:50 PM
GLMD meets a lot of criteria 🔥 Biotech history shows what’s possible when the right setup meets the right spark… 📈 $RCUS — $2 to $25+ on oncology momentum 📈 $CRBP — $0.90 to $9+ on FDA buzz 📈 $XBIO — under $1 to $6+ on low-float madness 📈 $MRNS — $1.50 to $13+ on epilepsy pipeline news ⬇️⬇️⬇️⬇️ Now look at $GLMD 🔹 Trading under $2 🔹 Book value near $12 🔹 Strong cash position 🔹 Biotech catalyst potential 🔹 Tight float 👀 Not a guarantee. Not advice. Just perspective. In biotech land, moves like these have happened before. GLMD has the ingredients. Now it’s about the catalyst.
0 · Reply
birdmine
birdmine Jun. 6 at 12:16 PM
$CRBP is it finally about to crest 9$?
0 · Reply
Cricket23
Cricket23 Jun. 3 at 6:58 PM
$CRBP Very nice gain we are seeing from CRBP today! Have been doing due diligence on this company for a while now and I strongly believe they will turn things around and shareholders will be greatly rewarded! Their pipeline of products is too valuable for this company not to get recognition. CRBP was once at $60, let's see if management can ramp things up and get the stock price back to its former glory.
2 · Reply
silentmaxx
silentmaxx Jun. 3 at 2:20 PM
$CRBP
0 · Reply